CL2014000122A1 - Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades. - Google Patents

Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.

Info

Publication number: CL2014000122A1
Authority: CL; Chile
Prior art keywords: jak; indazole; alzheimer; asthma; arthritis
Prior art date: 2011-07-27

Application number

CL2014000122A

Other languages

English (en)

Inventor

Jotham Wadsworth Coe

Christoph Martin Dehnhardt

Peter Jones

Steen Wade Kortum

Yogesh Anil Sabnis

Florian Michel Wakenhut

Gavin Alistar Whitlock

Original Assignee

Pfizer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-27

Filing date

2014-01-16

Publication date

2014-08-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46826868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-01-16 Application filed by Pfizer Ltd filed Critical Pfizer Ltd

2014-08-18 Publication of CL2014000122A1 publication Critical patent/CL2014000122A1/es

Links

BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
208000035143 Bacterial infection Diseases 0.000 title 1
206010006458 Bronchitis chronic Diseases 0.000 title 1
206010009900 Colitis ulcerative Diseases 0.000 title 1
206010019280 Heart failures Diseases 0.000 title 1
229940122245 Janus kinase inhibitor Drugs 0.000 title 1
206010028735 Nasal congestion Diseases 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
206010039085 Rhinitis allergic Diseases 0.000 title 1
201000006704 Ulcerative Colitis Diseases 0.000 title 1
208000036142 Viral infection Diseases 0.000 title 1
201000010105 allergic rhinitis Diseases 0.000 title 1
206010003246 arthritis Diseases 0.000 title 1
208000006673 asthma Diseases 0.000 title 1
208000022362 bacterial infectious disease Diseases 0.000 title 1
206010006451 bronchitis Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000007451 chronic bronchitis Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000003612 virological effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Transplantation (AREA)

CL2014000122A 2011-07-27 2014-01-16 Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades. CL2014000122A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161512144P	2011-07-27	2011-07-27

Publications (1)

Publication Number	Publication Date
CL2014000122A1 true CL2014000122A1 (es)	2014-08-18

Family

ID=46826868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000122A CL2014000122A1 (es)	2011-07-27	2014-01-16	Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.

Country Status (30)

Country	Link
US (2)	US8575336B2 (es)
EP (1)	EP2736907B1 (es)
JP (1)	JP5579351B1 (es)
KR (1)	KR20140026627A (es)
CN (1)	CN103717599B (es)
AP (1)	AP2014007372A0 (es)
AR (1)	AR087348A1 (es)
AU (1)	AU2012288491A1 (es)
BR (1)	BR112014001801A2 (es)
CA (1)	CA2841882A1 (es)
CL (1)	CL2014000122A1 (es)
CO (1)	CO6862160A2 (es)
CR (1)	CR20140042A (es)
CU (1)	CU20140009A7 (es)
DO (1)	DOP2014000016A (es)
EA (1)	EA201490357A1 (es)
EC (1)	ECSP14013222A (es)
GT (1)	GT201400016A (es)
IL (1)	IL230662A0 (es)
MA (1)	MA35285B1 (es)
MD (1)	MD20140002A2 (es)
MX (1)	MX2014001004A (es)
NI (1)	NI201400005A (es)
PE (1)	PE20141059A1 (es)
PH (1)	PH12014500199A1 (es)
TN (1)	TN2014000033A1 (es)
TW (1)	TWI462922B (es)
UA (1)	UA108442C2 (es)
UY (1)	UY34220A (es)
WO (1)	WO2013014567A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11629148B2 (en)	2019-02-25	2023-04-18	Henan Medinno Pharmaceutical Technology Co., Ltd.	Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8575336B2 (en)	2011-07-27	2013-11-05	Pfizer Limited	Indazoles
CR20160525A (es) *	2014-05-14	2016-12-20	Pfizer	Pirazolopiridinas y pirazolopirimidinas
JP2018507236A (ja)	2015-03-04	2018-03-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	トリアゾロピリジン化合物及びその使用法
EA039043B1 (ru)	2015-04-22	2021-11-25	Райджел Фармасьютикалз, Инк.	Пиразольные соединения и способ получения и применения данных соединений
US10556901B2 (en)	2015-11-03	2020-02-11	Topivert Pharma Limited	4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
HK1252685A1 (zh)	2015-11-03	2019-05-31	Theravance Biopharma R&D Ip, Llc	用於治疗呼吸疾病的jak激酶抑制剂化合物
EP3712152B1 (en)	2015-11-03	2021-01-13	Topivert Pharma Limited	4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TW201720828A (zh)	2015-11-23	2017-06-16	赫孚孟拉羅股份公司	治療性化合物及組合物以及其使用方法
WO2017096262A1 (en)	2015-12-04	2017-06-08	Jomoco, Corp.	Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
EP3416967B1 (en)	2016-02-18	2022-02-09	F. Hoffmann-La Roche AG	Therapeutic compounds, compositions and methods of use thereof
JP7034942B2 (ja)	2016-05-05	2022-03-14	エフ．ホフマン－ラロシュアーゲー	ピラゾール誘導体、その組成物及び治療的使用
MY199070A (en) *	2016-06-01	2023-10-12	Bayer Pharma AG	Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
CN109890817B (zh)	2016-09-06	2022-06-17	豪夫迈·罗氏有限公司	8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
EP3562809B1 (en)	2016-12-29	2021-06-09	F. Hoffmann-La Roche AG	Pyrazolopyrimidine compounds and methods of use thereof
BR112019018648A2 (pt) *	2017-03-09	2020-06-16	Theravance Biopharma R&D Ip, Llc	Inibidores de jak contendo uma amida heterocíclica com 4 membros
CN110494434B (zh)	2017-03-14	2022-05-24	豪夫迈·罗氏有限公司	吡唑并氯苯基化合物、其组合物及其使用方法
CN110603255B (zh) *	2017-05-01	2023-02-10	施万生物制药研发Ip有限责任公司	Jak抑制剂化合物的结晶型式
US10406148B2 (en)	2017-05-01	2019-09-10	Theravance Biopharma R&D Ip, Llc	Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) *	2017-05-01	2019-07-17	Theravance Biopharma R&D Ip Llc	Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2018215389A1 (en)	2017-05-22	2018-11-29	F. Hoffmann-La Roche Ag	Therapeutic compounds and compositions, and methods of use thereof
CN110678467B (zh)	2017-05-22	2023-06-13	豪夫迈·罗氏有限公司	治疗化合物和组合物及其使用方法
EP3740488A1 (en)	2018-01-15	2020-11-25	F. Hoffmann-La Roche AG	Pyrazolopyrimidine compounds as jak inhibitors
CA3108848A1 (en) *	2018-09-04	2020-03-12	Theravance Biopharma R&D Ip, Llc	Process for preparing jak inhibitors and intermediates thereof
PT3837258T (pt) *	2018-09-04	2024-06-20	Theravance Biopharma R&D Ip Llc	Amidas de dimetil amino azetidina como inibidores de jak
WO2020051139A1 (en) *	2018-09-04	2020-03-12	Theravance Biopharma R&D Ip, Llc	5 to 7 membered heterocyclic amides as jak inhibitors
MX2021004582A (es)	2018-10-29	2021-06-15	Theravance Biopharma R&D Ip Llc	Compuesto 2-azabiciclo hexano inhibidor de jak.
CN114075199B (zh) *	2020-08-14	2026-03-10	河南迈英诺医药科技有限公司	Jak抑制剂化合物及其用途
CN114075200A (zh) *	2020-08-14	2022-02-22	河南迈英诺医药科技有限公司	用于治疗重症肺炎的jak抑制剂化合物
CA3140024A1 (en)	2019-06-18	2020-12-24	Mark Edward Zak	Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
US20200399274A1 (en)	2019-06-18	2020-12-24	Genentech, Inc.	Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2020257143A1 (en)	2019-06-18	2020-12-24	Genentech, Inc.	Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
CN121159524A (zh)	2019-08-30	2025-12-19	里格尔药品股份有限公司	吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
WO2021136345A1 (zh) *	2019-12-30	2021-07-08	路良	Jak抑制剂化合物及其用途
TW202144343A (zh)	2020-03-02	2021-12-01	美商施萬生物製藥研發 Ip有限責任公司	Jak抑制劑化合物之結晶水合物
WO2021185305A1 (zh) *	2020-03-18	2021-09-23	四川海思科制药有限公司	一种吲唑衍生物及其在医药上的应用
WO2022187303A1 (en)	2021-03-03	2022-09-09	Rigel Pharmaceuticals, Inc.	A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202317550A (zh)	2021-06-25	2023-05-01	美商施萬生物製藥研發 Ip有限責任公司	作為jak抑制劑之咪唑吲唑化合物
JP2025513716A (ja)	2022-03-23	2025-04-30	ライジェル・ファーマシューティカルズ・インコーポレイテッド	Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物
CN117343063A (zh) *	2022-07-04	2024-01-05	河南迈英诺医药科技有限公司	作为trk抑制剂和/或ret抑制剂的化合物及其用途
AU2024323272A1 (en) *	2023-08-11	2026-02-26	Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd.	Jak inhibitor compound and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
JP2002542245A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	置換イミダゾール、それらの製造および使用
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU2004238508B2 (en)	2003-05-13	2009-11-19	F. Hoffmann-La Roche Ag	Imidazo-benzothiazoles
US7884109B2 (en) *	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
WO2007002313A2 (en)	2005-06-24	2007-01-04	Bristol-Myers Squibb Company	Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US8648069B2 (en) *	2007-06-08	2014-02-11	Abbvie Inc.	5-substituted indazoles as kinase inhibitors
TWI453207B (zh)	2008-09-08	2014-09-21	Signal Pharm Llc	胺基三唑并吡啶，其組合物及使用其之治療方法
EP2373626B1 (en) *	2008-12-18	2016-08-24	Nerviano Medical Sciences S.r.l.	Substituted indazole derivatives active as kinase inhibitors
WO2010090537A2 (en)	2009-02-05	2010-08-12	Benjamin Bell	A continuous flow worm farm
KR101127161B1 (ko) *	2009-07-13	2012-03-20	한국화학연구원	테트라히드로이미다조피리딘기가 치환된 퀴놀리논 화합물
JP2013501792A (ja) *	2009-08-10	2013-01-17	サミュメッドリミテッドライアビリティカンパニー	Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
EP2987487B1 (en) *	2009-08-10	2020-10-07	Samumed, LLC	Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
AR078012A1 (es) *	2009-09-01	2011-10-05	Incyte Corp	Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
US8575336B2 (en)	2011-07-27	2013-11-05	Pfizer Limited	Indazoles

2012
- 2012-07-05 US US13/542,153 patent/US8575336B2/en not_active Expired - Fee Related
- 2012-07-11 WO PCT/IB2012/053546 patent/WO2013014567A1/en not_active Ceased
- 2012-07-11 EA EA201490357A patent/EA201490357A1/ru unknown
- 2012-07-11 CN CN201280037293.XA patent/CN103717599B/zh not_active Expired - Fee Related
- 2012-07-11 EP EP12756557.0A patent/EP2736907B1/en active Active
- 2012-07-11 AU AU2012288491A patent/AU2012288491A1/en not_active Abandoned
- 2012-07-11 UA UAA201400660A patent/UA108442C2/ru unknown
- 2012-07-11 MD MDA20140002A patent/MD20140002A2/ro not_active Application Discontinuation
- 2012-07-11 JP JP2014522177A patent/JP5579351B1/ja not_active Expired - Fee Related
- 2012-07-11 CA CA2841882A patent/CA2841882A1/en not_active Abandoned
- 2012-07-11 MX MX2014001004A patent/MX2014001004A/es not_active Application Discontinuation
- 2012-07-11 BR BR112014001801A patent/BR112014001801A2/pt not_active IP Right Cessation
- 2012-07-11 AP AP2014007372A patent/AP2014007372A0/xx unknown
- 2012-07-11 PE PE2014000128A patent/PE20141059A1/es not_active Application Discontinuation
- 2012-07-11 KR KR1020147001773A patent/KR20140026627A/ko not_active Abandoned
- 2012-07-11 PH PH1/2014/500199A patent/PH12014500199A1/en unknown
- 2012-07-26 TW TW101127026A patent/TWI462922B/zh not_active IP Right Cessation
- 2012-07-26 UY UY0001034220A patent/UY34220A/es not_active Application Discontinuation
- 2012-07-26 AR ARP120102730A patent/AR087348A1/es unknown
2013
- 2013-09-30 US US14/041,387 patent/US8895544B2/en not_active Expired - Fee Related
2014
- 2014-01-16 CL CL2014000122A patent/CL2014000122A1/es unknown
- 2014-01-21 TN TNP2014000033A patent/TN2014000033A1/fr unknown
- 2014-01-24 GT GT201400016A patent/GT201400016A/es unknown
- 2014-01-24 NI NI201400005A patent/NI201400005A/es unknown
- 2014-01-26 IL IL230662A patent/IL230662A0/en unknown
- 2014-01-27 DO DO2014000016A patent/DOP2014000016A/es unknown
- 2014-01-27 CU CU2014000009A patent/CU20140009A7/es unknown
- 2014-01-27 MA MA36716A patent/MA35285B1/fr unknown
- 2014-01-27 CO CO14015917A patent/CO6862160A2/es active IP Right Grant
- 2014-01-27 CR CR20140042A patent/CR20140042A/es unknown
- 2014-02-27 EC ECSP14013222 patent/ECSP14013222A/es unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11629148B2 (en)	2019-02-25	2023-04-18	Henan Medinno Pharmaceutical Technology Co., Ltd.	Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors
US12180215B2 (en)	2019-02-25	2024-12-31	Henan Medinno Pharmaceutical Technology Co., Ltd.	Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors

Also Published As

Publication number	Publication date
UY34220A (es)	2013-02-28
AU2012288491A1 (en)	2014-01-30
PH12014500199A1 (en)	2014-03-03
KR20140026627A (ko)	2014-03-05
US8895544B2 (en)	2014-11-25
US8575336B2 (en)	2013-11-05
IL230662A0 (en)	2014-03-31
MD20140002A2 (ro)	2014-06-30
TN2014000033A1 (fr)	2015-07-01
WO2013014567A1 (en)	2013-01-31
CR20140042A (es)	2014-03-19
MX2014001004A (es)	2014-05-13
JP5579351B1 (ja)	2014-08-27
EA201490357A1 (ru)	2014-05-30
AP2014007372A0 (en)	2014-01-31
BR112014001801A2 (pt)	2017-02-14
US20140024634A1 (en)	2014-01-23
UA108442C2 (ru)	2015-04-27
CN103717599A (zh)	2014-04-09
PE20141059A1 (es)	2014-08-30
CU20140009A7 (es)	2014-03-26
CN103717599B (zh)	2015-11-25
EP2736907A1 (en)	2014-06-04
DOP2014000016A (es)	2014-07-15
EP2736907B1 (en)	2015-10-07
JP2014522865A (ja)	2014-09-08
TW201313712A (zh)	2013-04-01
CA2841882A1 (en)	2013-01-31
ECSP14013222A (es)	2014-03-31
GT201400016A (es)	2015-02-19
NI201400005A (es)	2014-04-23
AR087348A1 (es)	2014-03-19
CO6862160A2 (es)	2014-02-10
TWI462922B (zh)	2014-12-01
MA35285B1 (fr)	2014-07-03
US20130029968A1 (en)	2013-01-31

Publication	Publication Date	Title
CL2014000122A1 (es)	2014-08-18	Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
MD4800B1 (ro)	2022-03-31	Compuşi de aminopirimidinil ca inhibitori de JAK
MX2018015625A (es)	2019-03-06	Compuestos y composiciones para inhibir la actividad de shp2.
BR112018008966A2 (pt)	2018-11-27	compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112015022643A2 (pt)	2017-07-18	inibidores diidro-pirrolpiridinona
UY35963A (es)	2015-07-31	Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CL2013003051A1 (es)	2014-07-11	Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
DOP2014000008A (es)	2014-04-30	4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
BR112015028501A2 (pt)	2017-07-25	derivados de bipirazol como inibidores de jak
ECSP12012042A (es)	2013-05-31	Derivados de pirazol como inhibidores de jak
UA109010C2 (en)	2015-07-10	Morpholino pyrividines and their use in therapy
BR112015009942A2 (pt)	2017-07-11	derivados de tiofeno fundidos tricíclicos como inibidores de jak
MX2013011691A (es)	2014-05-27	Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
BR112015029970A2 (pt)	2017-07-25	inibidores de cinase
BR112014014452A2 (pt)	2017-06-13	derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
PH12015500713B1 (en)	2015-05-18	Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EP4356969A3 (en)	2024-05-22	Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
BR112012023660B8 (pt)	2021-05-25	usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
SG10201804026WA (en)	2018-06-28	Inhibitors of influenza viruses replication
CN107406464A8 (zh)	2018-01-12	精氨酸酶抑制剂及其治疗用途
MX347692B (es)	2017-05-09	Inhibidores del virus de la hepatitis c.
BR112015023891A2 (pt)	2017-07-18	composto, composição farmacêutica, e, uso de um composto
PH12015502589A1 (en)	2016-02-29	4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
PH12016500042A1 (en)	2016-03-28	Stabilized pharmaceutical dosage forms comprising atrasentan
EA201790072A1 (ru)	2017-11-30	Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы